ERYSO · Engineered erythrocytes and erythrocyte extracellular vesicles for advanced Photodynamic and Sonodynamic therapy
„Хоризонт Европа“ — Действия „Мария Склодовска-Кюри“
- Период
- 2027-01-01 → 2030-12-31
- Финансиране от ЕС
- 1 788 570 €
- Участници
- 14
- Схема
- HORIZON-TMA-MSCA-SE
Линиите свързват координатора с партньорите.
Накратко на български
Модифицирани червени кръвни клетки и техните везикули се използват за доставка на кислород и лекарства до туморите чрез светлина, звук и магнити. Това помага за подобряване на ефективността на терапията в зони с ниско съдържание на кислород и намалява страничните ефекти.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Цел на проекта
ERYSO aims to develop innovative therapeutic solutions based on photodynamic (PDT), and sonodynamic (SDT) therapies usingengineered red blood cells (RBCs) and extracellular vesicles (EVs) derived from RBCs in combination with magnetothermal (MHT)therapy. Both RBCs and RBC-derived EVs are characterized by their ability to transport hemoglobin, the body's natural oxygen carrier,and exhibit long circulation times, providing a unique advantage for therapeutic delivery. Encapsulating photosensitizers (PSs) andengineering these carriers for tumor targeting addresses a major limitation of existing PDT and SDT solutions, hypoxic tumor regions, by delivering oxygen directly to these areas, enhancing therapy efficacy. Combining PDT and SDT with MHT further amplifiestherapeutic outcomes, providing a multimodal approach to tumor eradication.Magnetic nanoparticles for MHT or titanium oxide nanoparticles for SDT will be encapsulated in the carriers to enable combination oftherapies. Tumor targeting will be achieved by functionalizing RBC glycocalyx with targeting peptides or incorporating functionalizedlipids into EVs. Enhanced tumor uptake of EVs and RBCs will be facilitated through the Focus Ultrasound (FUS) technique, whichtemporarily permeabilizes the blood-tumor barrier. Tumor targeting and oxygen delivery will be monitored using advancedmolecular imaging techniques such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography(SPECT). Therapeutic efficacy will be evaluated in relevant tumor models, combining molecular imaging and histopathologicalanalysis.The project envisions developing personalized therapies based on autologous patient components, ensuring localized treatmentwith reduced side effects. By leveraging the natural compatibility of RBCs and EVs and integrating cutting-edge targeting and deliverytechnologies, ERYSO advances the potential of personalized and multimodal cancer therapies.
Оригинален текст от CORDIS (на английски).
Участници
- ASOCIACION CENTRO DE INVESTIGACION COOPERATIVA EN BIOMATERIALES- CIC biomaGUNE · San SebastianКоординаторИспания
- CHULALONGKORN UNIVERSITY · BangkokТайланд
- DANUBE PRIVATE UNIVERSITY GMBH · KREMS-STEINАвстрия
- FRIEDRICH-ALEXANDER-UNIVERSITAET ERLANGEN-NUERNBERG · ErlangenГермания
- MAHIDOL UNIVERSITY · NAKHON PATHOMТайланд
- MAIBE SRL · ROMAИталия
- Prove Innomed Company Limited · NonthaburiТайланд
- TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY · HaifaИзраел
- TRAKIYSKI UNIVERSITET · Stara ZagoraБългария
- UNIVERSIDAD DE BUENOS AIRES · Buenos AiresАржентина
- UNIVERSIDAD NACIONAL DEL SUR · Bahia BlancaАржентина
- UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA · RomaИталия
- UNIVERSITY OF MAURITIUS · ReduitМавриций
- YAYASAN PERGURUAN TINGGI KRISTEN PETRA · SURABAYAИндонезия
Връзки
Данни: CORDIS, © Европейски съюз